Verteporfin

Ocular photodynamic therapy (OPT) with intravenous verteporfin is nationally covered for neovascular (exudative) AMD when lesions are predominately classic subfoveal CNV (classic component ≥50%) or for subfoveal occult or minimally classic CNV that are small (≤4 disc areas) and have documented progression within the prior 3 months. An initial fluorescein angiogram is required to classify lesions, subsequent assessment requires OCT or FA, and verteporfin must be given IV incident to a physician's service; juxtafoveal/extrafoveal CNV, inability to obtain FA, and atrophic/dry AMD are not nationally covered.

"OPT with verteporfin is covered for neovascular (exudative) age-related macular degeneration (AMD) with predominately classic subfoveal choroidal neovascularization (CNV) lesions, defined as classi..."

Sign up to see full coverage criteria, indications, and limitations.